Filing Flows › Comparisons › ADMA vs IOVA
Adma Biologics vs Iovance Biotherapeutics: ADMA and IOVA compared
Adma Biologics is the larger company: $141M of revenue in its latest quarter (Q3 2026) against $121M for Iovance Biotherapeutics (Q3 2026). Iovance Biotherapeutics is growing faster (+80% against +5% a year earlier). Adma Biologics is more profitable, with an operating margin of 48.0% against -19.7%.
Where the money goes: ADMA and IOVA
Adma Biologics (ADMA) · Q3 2026
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Iovance Biotherapeutics (IOVA) · Q3 2026
Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%, net loss $22.3M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
| Adma Biologics (ADMA) | Iovance Biotherapeutics (IOVA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $141M | $121M |
| Revenue growth, Y/Y | +5% | +80% |
| Gross margin | 70.8% | — |
| Operating margin | 48.0% | -19.7% |
| Net earnings | $49.9M | −$22.3M |
| Net margin | 35.4% | -18.3% |
| Operating cash flow | $17.4M | −$4.5M |
| Free cash flow | $15.4M | — |
| Market value | — | $6.6B |
| Analysts’ mean target | — | $14.50 |
Questions
Which is bigger, Adma Biologics or Iovance Biotherapeutics?
Adma Biologics is the larger company: $141M of revenue in its latest quarter (Q3 2026) against $121M for Iovance Biotherapeutics (Q3 2026).
Is Adma Biologics or Iovance Biotherapeutics growing faster?
Iovance Biotherapeutics is growing faster (+80% against +5% a year earlier).
Which is more profitable, Adma Biologics or Iovance Biotherapeutics?
Adma Biologics is more profitable, with an operating margin of 48.0% against -19.7%.
More: Adma Biologics earnings · how Adma Biologics makes money · Iovance Biotherapeutics earnings · how Iovance Biotherapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.